seconds
FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations
FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA
Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings
Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Manipulated Alzheimer’s Trial Data
Cassava Sciences, SEC charges, Alzheimer’s drug, simufilam, manipulated trial data, settlement, misleading statements
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Misleading Alzheimer’s Drug Trial Claims
Cassava Sciences, SEC settlement, Alzheimer’s drug trial, misleading claims, data manipulation, simufilam, pharmaceutical fraud
SEC Staff Recommends Enforcement Action Against Allarity Over Potential Federal Securities Laws Violations
Allarity Therapeutics, SEC, Enforcement Action, Federal Securities Laws, Violations, Wells Notice, FDA, Dovitinib, Stenoparib